Abstract Search

ea0098c41 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate

L Pritzl Stephanie , Kusne Yael , R Halfdanarson Thorvardur , Hobday Timothy , Bassam Sonbol Mohamad , Tuba Kendi Ayse , Mangaonkar Abhishek , Gangat Naseema , Shah Mithun , M Patnaik Mrinal

Background: Peptide receptor radionuclide therapy (PRRT) is a form of targeted systemic radiopharmaceutical therapy that has been approved for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Persistent hematologic dysfunction is a recognized potential long-term toxicity after PRRT, including the development of hematologic malignancies and persistent cytopenias. Therapy-related myeloid neoplasms (t-MN) are a well-recognized entity that ...

1 shares

ea0098o9 | Other | NANETS2023

Prevalence of clonal hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to lutetium 177 Dotatate (Lu177): A prospective study

Bassam Sonbol Mohamad , Kusne Yael , Lasho Terra , Elsabbagh Zaid , Mangaonkar Abhishek , Ahn Daniel , Eiring Rachel , Hobday Timothy , Starr Jason , Bekaii-Saab Tanios , Patnaik Mrinal , Halfdanarson Thorvardur

Background: Lu177 has shown efficacy in advanced NET with significant hematologic toxicity, including therapy-related myeloid neoplasm (t-MN). CH is defined by acquisition of somatic mutations in hematopoietic stem cells with potential for expansion over time. In this study, we aimed to assess the prevalence of CH in NET patients (pts) prior to Lu177 along with the incidence of cytopenia in NET pts treated with lu177 based on the CH status at baselineMet...

0 shares

Endocrine Abstracts

Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate

Prevalence of clonal hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to lutetium 177 Dotatate (Lu177): A prospective study

BiosciAbstracts